Fig. 4
From: The potential of deferasirox as a novel therapeutic modality in gastric cancer
Synergistic effect of deferasirox and cisplatin. a, b AGS cells were treated with 0, 2.5, 5, 10, and 20 μM of deferasirox, either alone or in the presence of a fixed concentration of cisplatin (5 μM) for 48 h. AGS cells treated with deferasirox and cisplatin showed a significant decrease in cellular viability compared with cells treated with either deferasirox or cisplatin alone